Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Chemedimmune Inc
Profile last edited on: 10/23/19      CAGE: 7QZ81      UEI: PZAMDK8K1H59

Business Identifier: Cancer Immunotherapy: Boost T Cells to Clear Cancer
Year Founded
2016
First Award
2018
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1120 15th Street
Augusta, GA 30912
   (706) 721-2319
   N/A
   www.chemedimmune.com
Location: Single
Congr. District: 12
County: Columbia

Public Profile

Chemedimmune Inc, spun out of Augusta University, develops drug candidates that target colon cancer. The company uses ceramide analogs in combination with mAb therapy to expand the effectiveness of mAb immunotherapy to additional types of cancers which express Fas receptor on the cell membranes.

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$532,110
Phase II Dollars
$0
Total Awarded
$532,110

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 1 NIH $329,610
Project Title: OPN Neutralization Monoclonal Antibody 100G2 for Human Pancreatic Cancer Immunotherapy
2018 1 NIH $202,500
Project Title: Development of Ig7 as an Enhancer of Anti-Pd-1 Cancer Immunotherapy

Key People / Management

  Rick Darby -- CEO

  Iryna Lebedyava -- Co-Founder

  Kebin Liu -- Co-Founder

  Chunwan Lu -- CSO

  Priscilla S Redd -- Senior Scientist

Company News

May 31 2018
New grant to help research compound to treat colorectal cancer